Immunocore Holdings PLC

More Details of Immunocore Holdings PLC Company

Immunocore Holdings plc is a United Kingdom-based commercial-stage biotechnology company. The Company is engaged in the development of TCR bispecific immunotherapies, ImmTAX, which immunes mobilizing monoclonal TCRs Against X disease, designed to treat a range of diseases, including cancer, autoimmune and infectious disease. The Company has a clinical-stage pipeline of wholly owned and partnered programs across three different therapeutic areas: oncology, infectious diseases, and autoimmune and inflammation diseases. Its lead product, KIMMTRAK, is a TCR therapeutic for the treatment of patients with unresectable or metastatic uveal melanoma (mUM), in the United States, European Union, Canada, Australia and the United Kingdom. Its pipeline products include IMC-F106C, IMC-F115C, IMC-F119C, IMC-F117C, IMC-F113V, IMC-I109V, IMC-SII8AI, among others. Its clinical programs are being conducted with patients with a range of cancers including melanoma, lung, gastric and others.

Company Info

Ticker SymbolIMCR

Company nameImmunocore Holdings PLC

IPO dateFeb 05, 2021

CEODr. Bahija Jallal, Ph.D.

Number of employees493

Security typeDepository Receipt

Fiscal year-endFeb 05

Address92 Park Drive Milton Park

CityABINGDON

Stock exchangeNASDAQ Global Select Consolidated

CountryUnited Kingdom

Postal codeOX14 4RY

Phone441235438600

Websitehttps://www.immunocore.com/

Ticker SymbolIMCR

IPO dateFeb 05, 2021

CEODr. Bahija Jallal, Ph.D.

Company Executives

Name

Name/Position

Position

Shareholding

Change

Prof. John Bell

Independent Chairman of the Board

13.45K

--

Mr. Roy S. Herbst, M.D., Ph.D.

Non-Executive Independent Director

--

Mr. Clayton Robertson

Head of Investor Relations

--

Dr. Bahija Jallal, Ph.D.

Chief Executive Officer, Executive Director

--

Ms. Tina St. Leger

Chief Human Resources Officer

--

Dr. William Pao, M.D., Ph.D.

Non-Executive Independent Director

--

Mr. Ranjeev Krishana

Non-Executive Independent Director

--

Mr. Siddharth Kaul

Non-Executive Independent Director

--

Ms. Kristine Peterson

Non-Executive Independent Director

--

Prof. Peter Ratcliffe

Non-Executive Independent Director

--

Name

Name/Position

Position

Shareholding

Change

Prof. John Bell

Independent Chairman of the Board

13.45K

--

Mr. Roy S. Herbst, M.D., Ph.D.

Non-Executive Independent Director

--

Mr. Clayton Robertson

Head of Investor Relations

--

Dr. Bahija Jallal, Ph.D.

Chief Executive Officer, Executive Director

--

Ms. Tina St. Leger

Chief Human Resources Officer

--

Dr. William Pao, M.D., Ph.D.

Non-Executive Independent Director

--

Revenue Breakdown

Currency: USDUpdated: Sun, Jul 6

FY2024

FY2023

FY2023Q3

FY2023Q2

FY2022

FY2022Q3

FY2022Q2

FY2020

FY2019

No Data

By RegionUSD

Name

Revenue

Proportion

United States

226.69M

73.08%

Europe

73.22M

23.61%

International

10.08M

3.25%

Collaboration revenue

213.00K

0.07%

By Business

By Region

No Data

Shareholding Stats

Updated: Tue, Aug 19

Shareholders

Shareholder Types

Shareholders

Proportion

T. Rowe Price Investment Management, Inc.

14.03%

Wellington Management Company, LLP

10.19%

RTW Investments L.P.

9.66%

Fidelity Management & Research Company LLC

9.57%

PRIMECAP Management Company

7.49%

Other

49.07%

Shareholders

Proportion

T. Rowe Price Investment Management, Inc.

14.03%

Wellington Management Company, LLP

10.19%

RTW Investments L.P.

9.66%

Fidelity Management & Research Company LLC

9.57%

PRIMECAP Management Company

7.49%

Other

49.07%

Shareholder Types

Shareholders

Proportion

Investment Advisor

43.16%

Hedge Fund

25.23%

Investment Advisor/Hedge Fund

24.78%

Corporation

5.06%

Research Firm

2.61%

Venture Capital

1.18%

Private Equity

0.76%

Pension Fund

0.48%

Individual Investor

0.03%

Institutional Shareholding

Updated: Tue, Jul 1

Reporting Period

No. of institutions

Shares Held

Proportion

Change

2025Q2

293

49.19M

99.31%

-10.02M

2025Q1

304

50.82M

102.67%

-9.36M

2024Q4

304

48.99M

99.30%

-7.33M

2024Q3

299

49.26M

99.94%

-5.38M

2024Q2

298

47.15M

96.58%

+1.62M

2024Q1

283

47.77M

97.93%

+3.51M

2023Q4

262

40.76M

86.07%

-2.70M

2023Q3

246

44.95M

95.97%

-1.86M

2023Q2

236

43.68M

94.12%

-435.38K

2023Q1

218

40.62M

88.44%

-3.40M

Shareholder Activity

Name

Shares Held

Proportion

Change

Chg %

Date

T. Rowe Price Investment Management, Inc.

7.05M

14.25%

+351.61K

+5.25%

Mar 31, 2025

Wellington Management Company, LLP

6.13M

12.39%

-485.33K

-7.33%

Mar 31, 2025

RTW Investments L.P.

4.87M

9.84%

--

Mar 31, 2025

Fidelity Management & Research Company LLC

4.81M

9.71%

+23.88K

+0.50%

Mar 31, 2025

PRIMECAP Management Company

2.68M

5.41%

+10.10K

+0.38%

Mar 31, 2025

Eli Lilly Vostok SA Geneva

2.55M

5.15%

--

Mar 21, 2025

Bellevue Asset Management AG

1.22M

2.47%

+16.33K

+1.35%

Mar 31, 2025

Baker Bros. Advisors LP

2.32M

4.69%

+807.34K

+53.28%

Mar 31, 2025

Tang Capital Management, LLC

1.92M

3.87%

+360.11K

+23.15%

Mar 31, 2025

Deep Track Capital LP

1.41M

2.85%

+892.03K

+171.75%

Mar 31, 2025

Related ETFs

Updated: Sat, Sep 6

Name

Proportion

First Trust IPOX Europe Equity Opportunities ETF

0%

Goldman Sachs Innovate Equity ETF

0%

iShares Health Innovation Active ETF

0%

Fidelity Fundamental Small-Mid Cap ETF

0%

First Trust IPOX Europe Equity Opportunities ETF

Proportion0%

Goldman Sachs Innovate Equity ETF

Proportion0%

iShares Health Innovation Active ETF

Proportion0%

Fidelity Fundamental Small-Mid Cap ETF

Proportion0%

Dividend

A total of 0.00 USD has been distributed in dividends over the past 5 years.

Date

Dividend

Record Date

Payment Date

Ex-dividend Date

No Data

Stock Split

Date

Type

Ratio

No Data

Date

Type

Ratio

No Data

32.600USD

Immunocore Holdings PLC

32.600

Overview

Company

Financials

Analysis